SAN JUAN CAPISTRANO, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it has declared a quarterly cash dividend of $0.06 per share of Ensign common stock, payable on or before January 31, 2024, to shareholders of record as of December 31, 2023. “We are pleased to announce our twenty-first consecutive annual dividend increase, which reflects our strong market position and continued commitment to return value to our shareholders,” commented Barry Port, Ensign's Chief Executive Officer. “We look forward to continued growth and are optimistic about our long-term prospects,” he added.
Ensign has been a dividend-paying company since 2002.
About Ensign ™
The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 297 healthcare facilities in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.
Contact Information
The Ensign Group, Inc., (949) 487-9500, This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$144.50 |
Daily Change: | -1.18 -0.81 |
Daily Volume: | 61,995 |
Market Cap: | US$8.250B |
November 13, 2024 November 04, 2024 October 29, 2024 October 24, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB